Sepsis Pathophysiology, Chronic Critical Illness, and Persistent Inflammation-Immunosuppression and Catabolism Syndrome

Objectives: To provide an appraisal of the evolving paradigms in the pathophysiology of sepsis and propose the evolution of a new phenotype of critically ill patients, its potential underlying mechanism, and its implications for the future of sepsis management and research. Design: Literature search using PubMed, MEDLINE, EMBASE, and Google Scholar. Measurements and Main Results: Sepsis remains one of the most debilitating and expensive illnesses, and its prevalence is not declining. What is changing is our definition(s), its clinical course, and how we manage the septic patient. Once thought to be predominantly a syndrome of over exuberant inflammation, sepsis is now recognized as a syndrome of aberrant host protective immunity. Earlier recognition and compliance with treatment bundles has fortunately led to a decline in multiple organ failure and in-hospital mortality. Unfortunately, more and more sepsis patients, especially the aged, are suffering chronic critical illness, rarely fully recover, and often experience an indolent death. Patients with chronic critical illness often exhibit “a persistent inflammation-immunosuppression and catabolism syndrome,” and it is proposed here that this state of persisting inflammation, immunosuppression and catabolism contributes to many of these adverse clinical outcomes. The underlying cause of inflammation-immunosuppression and catabolism syndrome is currently unknown, but there is increasing evidence that altered myelopoiesis, reduced effector T-cell function, and expansion of immature myeloid-derived suppressor cells are all contributory. Conclusions: Although newer therapeutic interventions are targeting the inflammatory, the immunosuppressive, and the protein catabolic responses individually, successful treatment of the septic patient with chronic critical illness and persistent inflammation-immunosuppression and catabolism syndrome may require a more complementary approach.

[1]  F. Brunkhorst,et al.  Sepsis-3 , 2017, Der Internist.

[2]  B. Brumback,et al.  Human Myeloid-derived Suppressor Cells are Associated With Chronic Immune Suppression After Severe Sepsis/Septic Shock , 2017, Annals of surgery.

[3]  R. Bellomo,et al.  Timing of onset and burden of persistent critical illness in Australia and New Zealand: a retrospective, population-based, observational study. , 2016, The Lancet. Respiratory medicine.

[4]  Tezcan Ozrazgat-Baslanti,et al.  The Pattern of Longitudinal Change in Serum Creatinine and 90-Day Mortality After Major Surgery , 2016, Annals of surgery.

[5]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[6]  T. Rea,et al.  Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[7]  P. Pickkers,et al.  Danger in the Intensive Care Unit: Damps in Critically Ill Patients , 2016, Shock.

[8]  C. Georgescu,et al.  Epidemiology of severe sepsis: 2008-2012. , 2016, Journal of critical care.

[9]  L. Fabbri,et al.  Chronic critical illness: the price of survival , 2015, European Journal of Clinical Investigation.

[10]  T. Kielian,et al.  Interleukin‐10 production by myeloid‐derived suppressor cells contributes to bacterial persistence during Staphylococcus aureus orthopedic biofilm infection , 2015, Journal of leukocyte biology.

[11]  P. Parizel,et al.  The course of diaphragm atrophy in ventilated patients assessed with ultrasound: a longitudinal cohort study , 2015, Critical Care.

[12]  Sun-Mee Lee,et al.  DAMPs activating innate immune responses in sepsis , 2015, Ageing Research Reviews.

[13]  Y. Meirow,et al.  Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate , 2015, Front. Immunol..

[14]  R. Dellinger,et al.  Foreword. The Future of Sepsis Performance Improvement. , 2015, Critical care medicine.

[15]  Yan Yang,et al.  Diagnostic and prognostic value of myeloid-related protein complex 8/14 for sepsis. , 2015, The American journal of emergency medicine.

[16]  W. Garrett,et al.  CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function , 2015, Cell reports.

[17]  A. S. Colombo,et al.  Physical activity, muscle strength, and exercise capacity 3 months after severe sepsis and septic shock , 2015, Intensive Care Medicine.

[18]  Cheng Cheng Tan,et al.  The Surviving Sepsis Campaign bundles and outcome: results from the International Multicentre Prevalence Study on Sepsis (the IMPreSS study) , 2015, Intensive Care Medicine.

[19]  Xue-guang Zhang,et al.  Circulating CD14+HLA-DR−/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC , 2015, Tumor Biology.

[20]  F. Moore,et al.  Persistent inflammatory, immunosuppressed, catabolic syndrome (PICS): A new phenotype of multiple organ failure. , 2015, Journal of advanced nutritional and human metabolism.

[21]  R. Hotchkiss,et al.  Interleukin-7 and Anti–Programmed Cell Death 1 Antibody Have Differing Effects to Reverse Sepsis-Induced Immunosuppression , 2015, Shock.

[22]  D. Annane,et al.  Critical care evidence--new directions. , 2015, JAMA.

[23]  D. Angus,et al.  The Epidemiology of Chronic Critical Illness in the United States* , 2015, Critical care medicine.

[24]  P. Evans,et al.  Long Term Health-Related Quality of Life in Survivors of Sepsis in South West Wales: An Epidemiological Study , 2014, PloS one.

[25]  Chen Zhang,et al.  Myeloid-Derived Suppressor Cells Impair Alveolar Macrophages through PD-1 Receptor Ligation during Pneumocystis Pneumonia , 2014, Infection and Immunity.

[26]  L. Rydén,et al.  A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram‐positive cases , 2014, Journal of leukocyte biology.

[27]  E. Benjamin,et al.  Long-term outcomes following development of new-onset atrial fibrillation during sepsis. , 2014, Chest.

[28]  E. Golanov,et al.  Brain Region-Specific Alterations in the Gene Expression of Cytokines, Immune Cell Markers and Cholinergic System Components during Peripheral Endotoxin-Induced Inflammation , 2014, Molecular medicine.

[29]  S. Lemeshow,et al.  Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7.5-year study , 2014, Intensive Care Medicine.

[30]  T. Yen,et al.  IL-6-stimulated CD11b+CD14+HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus , 2014, Oncotarget.

[31]  P. Fayers,et al.  Validation of the Consensus-Definition for Cancer Cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  R. Hotchkiss,et al.  Parallels between cancer and infectious disease. , 2014, New England Journal of Medicine.

[33]  Jinxiang Chen,et al.  The effect of immune microenvironment on the progression and prognosis of colorectal cancer , 2014, Medical Oncology.

[34]  Qiang Xu,et al.  Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation. , 2014, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[35]  L. Moldawer,et al.  Novel Role for Tumor-Induced Expansion of Myeloid-Derived Cells in Cancer Cachexia , 2014, The Journal of Immunology.

[36]  M. Heneka,et al.  Long-term cerebral consequences of sepsis , 2014, The Lancet Neurology.

[37]  Minho Chae,et al.  Serum amyloid A3 exacerbates cancer by enhancing the suppressive capacity of myeloid‐derived suppressor cells via TLR2‐dependent STAT3 activation , 2014, European journal of immunology.

[38]  Amber J. Giles,et al.  Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy , 2014, Science Translational Medicine.

[39]  S. Reis,et al.  Risk of cardiovascular events in survivors of severe sepsis. , 2014, American journal of respiratory and critical care medicine.

[40]  Markus G. Manz,et al.  Emergency granulopoiesis , 2014, Nature Reviews Immunology.

[41]  J. Marshall Why have clinical trials in sepsis failed? , 2014, Trends in molecular medicine.

[42]  K. Asehnoune,et al.  Prevalence and impact of frailty on mortality in elderly ICU patients: a prospective, multicenter, observational study , 2014, Intensive Care Medicine.

[43]  S. Bagshaw,et al.  Association between frailty and short- and long-term outcomes among critically ill patients: a multicentre prospective cohort study , 2014, Canadian Medical Association Journal.

[44]  D. Angus,et al.  Epidemiology of severe sepsis , 2013, Virulence.

[45]  N. Miyagawa,et al.  Plasma mitochondrial DNA levels in patients with trauma and severe sepsis: time course and the association with clinical status. , 2013, Journal of critical care.

[46]  M. Kelz,et al.  Orexinergic Activity Modulates Altered Vital Signs and Pituitary Hormone Secretion in Experimental Sepsis , 2013, Critical care medicine.

[47]  J. Talmadge,et al.  History of myeloid-derived suppressor cells , 2013, Nature Reviews Cancer.

[48]  Eileen Bulger,et al.  Skeletal muscle predicts ventilator-free days, ICU-free days, and mortality in elderly ICU patients , 2013, Critical Care.

[49]  S. Powers,et al.  Ventilator-induced diaphragm dysfunction: cause and effect. , 2013, American journal of physiology. Regulatory, integrative and comparative physiology.

[50]  A. Bihorac,et al.  Acute kidney injury is surprisingly common and a powerful predictor of mortality in surgical sepsis , 2013, The journal of trauma and acute care surgery.

[51]  B. Zhang,et al.  Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients , 2013, Cancer Immunology, Immunotherapy.

[52]  R. Hotchkiss,et al.  Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis , 2013, Critical Care.

[53]  C. Sprung,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012 , 2013, Intensive Care Medicine.

[54]  G. Blancho,et al.  Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance , 2012, Front. Immun..

[55]  L. Moldawer,et al.  Persistent inflammation and immunosuppression: A common syndrome and new horizon for surgical intensive care , 2012, The journal of trauma and acute care surgery.

[56]  H. Wunsch,et al.  Population Burden of Long‐Term Survivorship After Severe Sepsis in Older Americans , 2012, Journal of The American Geriatrics Society.

[57]  C. Cox Persistent Systemic Inflammation in Chronic Critical Illness , 2012, Respiratory Care.

[58]  C. Alauzet,et al.  Myeloid-derived suppressor cells control microbial sepsis , 2012, Intensive Care Medicine.

[59]  D. Needham,et al.  Improving long-term outcomes after discharge from intensive care unit: Report from a stakeholders' conference* , 2012, Critical care medicine.

[60]  Xiaopei Huang,et al.  Myeloid-Derived Suppressor Cells Regulate Natural Killer Cell Response to Adenovirus-Mediated Gene Transfer , 2012, Journal of Virology.

[61]  Arthur S Slutsky,et al.  Ventilator-induced lung injury and sepsis: two sides of the same coin? , 2011, Minerva anestesiologica.

[62]  M. J. Hall,et al.  Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. , 2011, NCHS data brief.

[63]  Lyle L. Moldawer,et al.  A Paradoxical Role for Myeloid-Derived Suppressor Cells in Sepsis and Trauma , 2011, Molecular medicine.

[64]  K. Langa,et al.  Long-term cognitive impairment and functional disability among survivors of severe sepsis. , 2010, JAMA.

[65]  R. Hotchkiss,et al.  Immunotherapy for sepsis--a new approach against an ancient foe. , 2010, The New England journal of medicine.

[66]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[67]  R. Hotchkiss,et al.  IL-7 Promotes T Cell Viability, Trafficking, and Functionality and Improves Survival in Sepsis , 2010, The Journal of Immunology.

[68]  Javier Llorca,et al.  Impact of the Surviving Sepsis Campaign protocols on hospital length of stay and mortality in septic shock patients: Results of a three-year follow-up quasi-experimental study* , 2010, Critical care medicine.

[69]  S. Akira,et al.  Cutting Edge: Bacterial Infection Induces Hematopoietic Stem and Progenitor Cell Expansion in the Absence of TLR Signaling , 2010, The Journal of Immunology.

[70]  Richard Beale,et al.  The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis , 2010, Intensive Care Medicine.

[71]  C. Coopersmith,et al.  IL-15 Prevents Apoptosis, Reverses Innate and Adaptive Immune Dysfunction, and Improves Survival in Sepsis , 2009, The Journal of Immunology.

[72]  V. Bronte Myeloid‐derived suppressor cells in inflammation: Uncovering cell subsets with enhanced immunosuppressive functions , 2009, European journal of immunology.

[73]  A. Kalil,et al.  Prevalence and mortality associated with cytomegalovirus infection in nonimmunosuppressed patients in the intensive care unit* , 2009, Critical care medicine.

[74]  E. Ruokonen,et al.  Long-term outcome and quality-adjusted life years after severe sepsis* , 2009, Critical care medicine.

[75]  B. Rini,et al.  Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients , 2009, Clinical Cancer Research.

[76]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[77]  B. Casserly,et al.  The compensatory anti-inflammatory response syndrome (CARS) in critically ill patients. , 2008, Clinics in chest medicine.

[78]  A. Limaye,et al.  Reactivation of Cytomegalovirus Infection in Critically Ill Immunocompetent Patients—Reply , 2008 .

[79]  S. Rankin,et al.  Neutrophil mobilization and clearance in the bone marrow , 2008, Immunology.

[80]  G. Rubenfeld,et al.  Cytomegalovirus reactivation in critically ill immunocompetent patients. , 2008, JAMA.

[81]  K. Gupta,et al.  Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer , 2007, Nature Medicine.

[82]  L. Moldawer,et al.  MyD88-dependent expansion of an immature GR-1+CD11b+ population induces T cell suppression and Th2 polarization in sepsis , 2007, The Journal of experimental medicine.

[83]  Sandy Schwemberger,et al.  THERMAL INJURY ELEVATES THE INFLAMMATORY MONOCYTE SUBPOPULATION IN MULTIPLE COMPARTMENTS , 2007, Shock.

[84]  H. Zeh,et al.  Arginine and immunity. , 2007, The Journal of nutrition.

[85]  J. Govert,et al.  Differences in one-year health outcomes and resource utilization by definition of prolonged mechanical ventilation: a prospective cohort study , 2007, Critical care.

[86]  Ingo Fricke,et al.  All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. , 2006, Cancer research.

[87]  C. Coopersmith,et al.  The systemic inflammatory response syndrome. , 2006, Microbes and infection.

[88]  J. Ochoa,et al.  CD11b+/Gr-1+ Myeloid Suppressor Cells Cause T Cell Dysfunction after Traumatic Stress1 , 2006, The Journal of Immunology.

[89]  F. Gao,et al.  The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study , 2005, Critical care.

[90]  L. Kaiser,et al.  Gemcitabine Selectively Eliminates Splenic Gr-1+/CD11b+ Myeloid Suppressor Cells in Tumor-Bearing Animals and Enhances Antitumor Immune Activity , 2005, Clinical Cancer Research.

[91]  V. Bronte,et al.  Regulation of immune responses by L-arginine metabolism , 2005, Nature Reviews Immunology.

[92]  G. Kelsoe,et al.  Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow , 2005, The Journal of experimental medicine.

[93]  Herwig Gerlach,et al.  Reply to Zandstra and van der Voort , 2004, Intensive Care Medicine.

[94]  Mitchell M. Levy,et al.  Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock , 2004, Critical care medicine.

[95]  P. Bach,et al.  The epidemiology and costs of chronic critical illness. , 2002, Critical care clinics.

[96]  L. Moldawer,et al.  Apoptosis in sepsis: a new target for therapeutic exploration , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[97]  R. Hotchkiss,et al.  Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte , 2000, Nature Immunology.

[98]  D. Heyland,et al.  Long-term health-related quality of life in survivors of sepsis. Short Form 36: A valid and reliable measure of health-related quality of life , 2000, Critical care medicine.

[99]  S. Korsmeyer,et al.  Prevention of lymphocyte cell death in sepsis improves survival in mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[100]  B. Giroir Mediators of septic shock: New approaches for interrupting the endogenous inflammatory cascade , 1993, Critical care medicine.

[101]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[102]  D. Remick,et al.  Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. , 1992, The Journal of clinical investigation.

[103]  J. Norton,et al.  A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice , 1991, The Journal of experimental medicine.

[104]  B. Beutler,et al.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.

[105]  Cyrus Chargari,et al.  Epstein-Barr virus reactivation in critically ill immunocompetent patients , 2015, Biomedical journal.

[106]  C. Divino,et al.  Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. , 2010, Cancer research.

[107]  Shannon S Carson,et al.  Chronic critical illness. , 2010, American journal of respiratory and critical care medicine.

[108]  L. Moldawer,et al.  MyD 88-dependent expansion of an immature GR-1 + CD 11 b + population induces T cell suppression and Th 2 polarization in sepsis , 2007 .

[109]  Gordon S Doig,et al.  Post-ICU mechanical ventilation at 23 long-term care hospitals: a multicenter outcomes study. , 2007, Chest.

[110]  S. Mocellin,et al.  Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation , 2007 .